In a survey, less than half of cancer patients and their family members said they were willing to participate in a clinical trial, and about a third of respondents said they had a positive perception ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Survey results add to evidence showing that more than half of US patients with mCSPC are still receiving androgen deprivation therapy (ADT) alone or ADT with a nonsteroidal antiandrogen.

All types of birth control evaluated were associated with an increased risk of any cancer, and most types of birth control were associated with an increased risk of breast cancer. Note: This ...

Outpatient management of cancer-associated PE had 30-day adverse outcome rates of 1.74% for all-cause mortality, 2.71% for major bleeding, and 1.26% for recurrent VTE. Outpatient management of ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic ...

The variability in levels of decision regret underscores the complexity of treatment decisions and the need for individualized patient support. Decision regret was a significant concern for women ...

In 37% of cases, patients said the doctor had little time to discuss patient-identified information. US cancer patients have reported positive and negative experiences when sharing patient ...

Multidisciplinary teams are essential in delivering comprehensive cancer care, yet access to dietitians remains limited in many oncology settings. Oncology nurses, with their expertise in patient ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Compared with patients with undetectable ctDNA levels in this study, patients with detectable ctDNA had an increased risk of inferior EFS at day 43. Circulating tumor DNA (ctDNA) levels appear to ...

The cumulative incidence of first CRB was 9.8% at 6 months, 16.6% at 12 months, and 23.9% at 24 months. Patients with cancer demonstrated an increased risk of clinically relevant bleeding (CRB ...